Darlene Dobkowski, Managing Editor for CURE® magazine, has been with the team since October 2020 and has covered health care in other specialties before joining MJH Life Sciences. She graduated from Emerson College with a Master’s degree in print and multimedia journalism. In her free time, she enjoys buying stuff she doesn’t need from flea markets, taking her dog everywhere and scoffing at decaf.
‘Cheers’ Actress Kirstie Alley Dies Shortly After Receiving Colon Cancer Diagnosis
December 6th 2022Actress Kirstie Alley, who is known for roles in “Cheers,” “Look Who’s Talking’” and other television shows and movies, died a short time after receiving a colon cancer diagnosis, according to a family statement.
Read More
FDA Approval of Elahere Represents a ‘Step Forward’ for Platinum-Resistant Ovarian Cancer Subset
November 22nd 2022One expert said that the FDA approval of the antibody-drug conjugate Elahere represents a new treatment option for patients with folate receptor alpha-positive, platinum resistant ovarian cancer.
Read More
Stem cell transplants may cause dysgeusia — a disorder that alters a person’s taste —in some patients with multiple myeloma, which is a type of blood cancer. This disorder may have a domino effect on quality of life, although levels may return to normal a few months after the procedure, an expert said.
Read More
How Patients With Cancer Can Best Care For Their Chemo Port
June 23rd 2022Care teams often implant a chemo port into patients with cancer to provide easy access for blood draws and to deliver treatments such as chemotherapy and antibiotics. Here, as part of its Heal at Home series, CURE® works with a nurse to provide a guide for patients to care for their port.
Read More
First Patient With Lymphoma Receives Novel Cell Therapy in Large-Scale Trial
April 5th 2022The plan is to assess the safety and efficacy of the genetically engineered cell therapy alongside high-dose chemotherapy and blood stem cell transplantation in approximately 150 patients with lymphoma.
Read More
“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of immunotherapy from palliative treatment in the metastatic setting to curative treatment in localized disease,” the study authors wrote.
Read More